Decision-making around antithrombotics for stroke prevention in atrial fibrillation: the health professionals' views

Yishen Wang1, Beata Bajorek2,3

  • 1Graduate School of Health-Pharmacy, The University of Technology Sydney, Sydney, NSW, 2007, Australia. Yishen.Wang@student.uts.edu.au.

Insights

Health professionals

Area of Science:

  • Cardiology
  • Pharmacology
  • Public Health

Background:

  • Stroke prevention in atrial fibrillation (AF) is complex due to patient factors and antithrombotic properties.
  • Decision-making challenges can lead to underutilization of antithrombotic therapy and poor outcomes.
  • Exploring health professionals' current views on antithrombotic therapy decision-making is crucial for improving stroke prevention.

Purpose of the Study:

  • To identify emerging themes in health professionals' perspectives on antithrombotic therapy decision-making for AF stroke prevention.
  • To understand the factors influencing treatment choices between warfarin and non-vitamin K antagonist oral anticoagulants (NOACs).

Main Methods:

  • Qualitative study using face-to-face interviews with pharmacists, specialists, general practitioners, and nurses.
  • Interviews conducted in Sydney, Australia (August-October 2014) until theme saturation.
  • Manual inductive coding of interview transcripts to identify key themes.

Main Results:

  • Comprehensive assessment is needed but often omits bleeding risk and medication safety.
  • Disciplinary differences exist: warfarin is often first-line, but NOACs are preferred by neurologists/hematologists.
  • GPs/specialists focus on prescription, while pharmacists/nurses emphasize patient medication management.

Conclusions:

  • Antithrombotic therapy decision-making is often preference-based rather than systematic.
  • Varied disciplinary focus can fragment the decision-making process.
  • Improving stroke prevention requires addressing these varied perspectives and ensuring comprehensive patient assessment.

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
456
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.3K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
569
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
377